Frei E, Sallan S E
Cancer. 1978 Aug;42(2 Suppl):828-38. doi: 10.1002/1097-0142(197808)42:2+<828::aid-cncr2820420704>3.0.co;2-w.
Over the past thirty years, major progress has been achieved in the treatment of ALL. Many of the concepts, definitions, and principles of chemotherapy have and continue to be derived from studies in ALL. Major and continuing progress is ongoing for the various categories of treatment; that is, remission induction, treatment at sites of high risk for relapse (e. g., pharmacologic sanctuaries), cytoreductive therapy during complete remission, and duration of treatment. Rapid improvement in our understanding of the pathogenesis of ALL and particularly the identification of immunologic and prognostic subcategories of ALL have major therapeutic implications which are in process of being realized. Current research is focused on the development of new chemotherapeutic agents, the more rational basis for the employment of chemotherapeutic agents in combination (cytokinetic, pharmacologic, and related studies), a better definition of the host-tumor relationship particularly with respect to immunologic response and iatrogenic manipulation of such responses, and in the area of supportive care and bone marrow transplantation.
在过去三十年里，急性淋巴细胞白血病（ALL）的治疗取得了重大进展。化疗的许多概念、定义和原则已经并将继续源自ALL的研究。各类治疗都在不断取得重大进展，即缓解诱导、复发高危部位（如药物性庇护所）的治疗、完全缓解期的细胞减灭治疗以及治疗持续时间。我们对ALL发病机制的理解迅速提高，尤其是ALL免疫和预后亚类的识别，具有重大治疗意义，目前正在逐步实现。当前的研究集中在开发新的化疗药物、更合理地联合使用化疗药物（细胞动力学、药理学及相关研究）、更好地界定宿主与肿瘤的关系，特别是免疫反应以及对这种反应的医源性操纵，以及在支持治疗和骨髓移植领域。
